PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23372698-7	2013	CB(1) stimulation caused long-term inhibition of the ERK1/2 pathway.	cb(1)	0-5	mitogen-activated protein kinase 3	Mus musculus	53-59
23578490-0	2013	Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons.	cb(1)	51-56	fragile X messenger ribonucleoprotein 1	Mus musculus	0-4
23127915-14	2013	CB(1) or CB(2) antagonists completely blocked the anti-allodynic effects of both FAAH (URB597, URB937) and MGL (JZL184) inhibitors to mechanical and cold stimulation.	cb(1)	0-5	fatty acid amide hydrolase	Homo sapiens	81-85
23127915-14	2013	CB(1) or CB(2) antagonists completely blocked the anti-allodynic effects of both FAAH (URB597, URB937) and MGL (JZL184) inhibitors to mechanical and cold stimulation.	cb(1)	0-5	monoglyceride lipase	Homo sapiens	107-110
23127915-20	2013	The anti-allodynic effects of FAAH and MGL inhibitors are mediated by CB(1) and CB(2) cannabinoid receptors, whereas TRPV1, but not TRPA1, -dependent mechanisms contribute to the anti-allodynic efficacy of FAAH (but not MGL) inhibitors.	cb(1)	70-75	fatty acid amide hydrolase	Homo sapiens	30-34
23127915-20	2013	The anti-allodynic effects of FAAH and MGL inhibitors are mediated by CB(1) and CB(2) cannabinoid receptors, whereas TRPV1, but not TRPA1, -dependent mechanisms contribute to the anti-allodynic efficacy of FAAH (but not MGL) inhibitors.	cb(1)	70-75	monoglyceride lipase	Homo sapiens	39-42
23372698-8	2013	Consistently, pharmacological inhibition of the ERK1/2 pathway recapitulated the effects exerted by CB(1) activation on neuronal differentiation and maturation.	cb(1)	100-105	mitogen-activated protein kinase 3	Mus musculus	48-54
22431736-3	2012	However, at lower concentrations, AEA and other CB(1)-binding endocannabinoids dose-dependently stimulate melanin synthesis and enhance tyrosinase gene expression and activity (~3- and ~2-fold over controls at 1 muM).	cb(1)	48-53	tyrosinase	Homo sapiens	136-146
21595653-9	2012	MAPK activation in HEK293-GPR18 cells revealed novel pharmacology for known CB(1) and CB(2) receptor ligands at GPR18 receptors, including Delta(9) -THC, which activates MAPK at nanomolar concentrations, whereas WIN 55212-2, CP55940, JWH-133 and JWH-015, and arachidonyl-1-hydroxy-2-propylamide (R1-methanandamide) had no effect.	cb(1)	76-81	G protein-coupled receptor 18	Homo sapiens	26-31
21595653-9	2012	MAPK activation in HEK293-GPR18 cells revealed novel pharmacology for known CB(1) and CB(2) receptor ligands at GPR18 receptors, including Delta(9) -THC, which activates MAPK at nanomolar concentrations, whereas WIN 55212-2, CP55940, JWH-133 and JWH-015, and arachidonyl-1-hydroxy-2-propylamide (R1-methanandamide) had no effect.	cb(1)	76-81	G protein-coupled receptor 18	Homo sapiens	112-117
19502530-6	2009	The novel MAGL inhibitor, 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) also attenuated mechanical and cold allodynia via a CB(1), but not a CB(2), receptor mechanism of action.	cb(1)	171-176	monoglyceride lipase	Mus musculus	10-14
22192465-3	2012	This effect was accompanied by increased phosphorylation of DARPP-32 at threonine 34, which was partially blocked by CB(1) antagonism.	cb(1)	117-122	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	60-68
21873455-2	2011	In this study, we demonstrate that APC function is enhanced specifically in the absence of CB(1) and CB(2) signaling, resulting in an exacerbated immune response phenotype.	cb(1)	91-96	APC, WNT signaling pathway regulator	Mus musculus	35-38
21333643-9	2011	Similar to our neurotransmission data, CP47,497-C8 internalized CB(1) in a fashion indistinguishable from JWH018.	cb(1)	64-69	beaded filament structural protein 2	Homo sapiens	39-47
20862263-12	2010	In genotype 3 patients, CB(1) correlated with SREBP-1c and its downstream target FASN (SREBP-1c; R=0.37, FASN; R=0.39, p<0.05 for both).	cb(1)	24-29	sterol regulatory element binding transcription factor 1	Homo sapiens	46-54
20862263-12	2010	In genotype 3 patients, CB(1) correlated with SREBP-1c and its downstream target FASN (SREBP-1c; R=0.37, FASN; R=0.39, p<0.05 for both).	cb(1)	24-29	fatty acid synthase	Homo sapiens	81-85
20862263-12	2010	In genotype 3 patients, CB(1) correlated with SREBP-1c and its downstream target FASN (SREBP-1c; R=0.37, FASN; R=0.39, p<0.05 for both).	cb(1)	24-29	sterol regulatory element binding transcription factor 1	Homo sapiens	87-95
20862263-12	2010	In genotype 3 patients, CB(1) correlated with SREBP-1c and its downstream target FASN (SREBP-1c; R=0.37, FASN; R=0.39, p<0.05 for both).	cb(1)	24-29	fatty acid synthase	Homo sapiens	105-109
20047331-2	2010	On the basis of their extended CB(1) antagonist pharmacophore, hybrid molecules exhibiting cannabinoid CB(1) receptor antagonistic as well as acetylcholinesterase (AChE) inhibiting activities were designed.	cb(1)	31-36	acetylcholinesterase (Cartwright blood group)	Homo sapiens	142-162
20047331-2	2010	On the basis of their extended CB(1) antagonist pharmacophore, hybrid molecules exhibiting cannabinoid CB(1) receptor antagonistic as well as acetylcholinesterase (AChE) inhibiting activities were designed.	cb(1)	31-36	acetylcholinesterase (Cartwright blood group)	Homo sapiens	164-168
20047331-5	2010	Molecular modeling studies revealed the presence of a binding pocket in the AChE enzyme which nicely accommodates the CB(1) pharmacophores of the target compounds 12, 13, 20, and 21.	cb(1)	118-123	acetylcholinesterase (Cartwright blood group)	Homo sapiens	76-80
21551239-7	2011	Coadministration of either CB(1) (SR141716A) or CB(2) (AM630) selective antagonists with JZL184 completely abolished the protective effect of MAGL inhibition on TNBS-induced colon alterations, thus demonstrating the involvement of both cannabinoid receptors.	cb(1)	27-32	monoglyceride lipase	Mus musculus	142-146
21282604-3	2011	In the basolateral amygdala complex, it has been demonstrated that CB(1) is particularly enriched in axon terminals of cholecystokinin (CCK)-positive GABAergic interneurons, induces short- and long-term depression at inhibitory synapses, and is involved in extinction of fear memory.	cb(1)	67-72	cholecystokinin	Homo sapiens	119-134
21282604-3	2011	In the basolateral amygdala complex, it has been demonstrated that CB(1) is particularly enriched in axon terminals of cholecystokinin (CCK)-positive GABAergic interneurons, induces short- and long-term depression at inhibitory synapses, and is involved in extinction of fear memory.	cb(1)	67-72	cholecystokinin	Homo sapiens	136-139
20660502-3	2010	Both LNCaP and PC3 cells expressed CB(1) and CB(2) receptors, and the CB(1)- and CB(2)-selective antagonists, AM281 and AM630, administered separately or together, reduced the anti-proliferative potencies of EPEA and EPA but not of DHEA or DHA in PC3 cells and of EPA but not of EPEA, DHEA or DHA in LNCaP cells.	cb(1)	35-40	BTG anti-proliferation factor 2	Homo sapiens	15-18
20531936-9	2010	Dual blockade of CB(1) and CB(2) receptor signaling prevented the resolution of postoperative allodynia and resulted in persistent over-expression of spinal Glial Fibrillary Acidic Protein (GFAP, an astrocytic marker) and phospho-p38 in astrocytes.	cb(1)	17-22	glial fibrillary acidic protein	Homo sapiens	157-188
20531936-9	2010	Dual blockade of CB(1) and CB(2) receptor signaling prevented the resolution of postoperative allodynia and resulted in persistent over-expression of spinal Glial Fibrillary Acidic Protein (GFAP, an astrocytic marker) and phospho-p38 in astrocytes.	cb(1)	17-22	glial fibrillary acidic protein	Homo sapiens	190-194
20531936-9	2010	Dual blockade of CB(1) and CB(2) receptor signaling prevented the resolution of postoperative allodynia and resulted in persistent over-expression of spinal Glial Fibrillary Acidic Protein (GFAP, an astrocytic marker) and phospho-p38 in astrocytes.	cb(1)	17-22	mitogen-activated protein kinase 14	Homo sapiens	230-233
19936621-0	2010	Anandamide extends platelets survival through CB(1)-dependent Akt signaling.	cb(1)	46-51	AKT serine/threonine kinase 1	Homo sapiens	62-65
19484221-5	2009	OBJECTIVE: The aim of the study was to explore the effect of inhibiting FAAH enzyme by URB597 on nicotine self-administration under a progressive ratio schedule and reinstatement of nicotine seeking, in comparison with the effect of the CB(1) antagonist rimonabant.	cb(1)	237-242	fatty-acid amide hydrolase-like	Rattus norvegicus	72-76
18987195-6	2008	The possibility that constitutive activity at the CB(1) receptor is required to maintain the TRPV1 receptor in a "sensitized" state was tested using CB(1) inverse agonists.	cb(1)	50-55	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	93-98
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	cb(1)	133-138	negative elongation factor complex member C/D, Th1l	Mus musculus	84-87
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	cb(1)	133-138	heart and neural crest derivatives expressed 2	Mus musculus	91-94
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	cb(1)	154-159	interferon gamma	Mus musculus	0-8
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	cb(1)	154-159	hemoglobin, beta adult minor chain	Mus musculus	62-67
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	cb(1)	154-159	hemoglobin, beta adult minor chain	Mus musculus	69-74
18792785-9	2009	Together, these results indicate that CB(1) and CB(2) mediate the THC-induced shift in T helper activity in L. pneumophila-infected mice, with CB(1) involved in suppressing IL-12Rbeta2 and CB(2) involved in enhancing GATA-3.	cb(1)	143-148	GATA binding protein 3	Mus musculus	217-223
19607961-15	2009	Furthermore, the inhibition of FAAH causes an accumulation of AEA but not 2-AG, which, being 200-fold more abundant than AEA in the brain, might differently modulate CB(1)-mediated behavioral responses.	cb(1)	166-171	fatty acid amide hydrolase	Homo sapiens	31-35
18804501-9	2008	Consequently, MOR-mediated signaling was attenuated after acute in vivo treatment with SR144528 in both CB(1) wild-type and CB(1) knockout mice.	cb(1)	104-109	opioid receptor, mu 1	Mus musculus	14-17
18804501-9	2008	Consequently, MOR-mediated signaling was attenuated after acute in vivo treatment with SR144528 in both CB(1) wild-type and CB(1) knockout mice.	cb(1)	124-129	opioid receptor, mu 1	Mus musculus	14-17
19115376-5	2009	MD induced a significant decrease in CB(1) immunoreactivity (more marked in males than in females), which was mainly associated with fibers in the strata pyramidale and radiatum of CA1 and in the strata oriens, pyramidale, and radiatum of CA3.	cb(1)	37-42	carbonic anhydrase 1	Rattus norvegicus	181-184
19115376-5	2009	MD induced a significant decrease in CB(1) immunoreactivity (more marked in males than in females), which was mainly associated with fibers in the strata pyramidale and radiatum of CA1 and in the strata oriens, pyramidale, and radiatum of CA3.	cb(1)	37-42	carbonic anhydrase 3	Rattus norvegicus	239-242
19233486-1	2009	Preliminary data presented at conferences and in the patent literature introduced the possibility the orphan receptor GPR55 might account for some of the well-documented non-CB(1), non-CB(2) effects reported for certain cannabinoid ligands.	cb(1)	174-179	G protein-coupled receptor 55	Homo sapiens	118-123
18851692-6	2008	FAAH inhibitors, compared with direct CB(1) agonists, exhibit distinct pharmacological properties that quell adverse cannabinoid effects and widen the therapeutic window.	cb(1)	38-43	fatty acid amide hydrolase	Homo sapiens	0-4
17585904-6	2007	The endogenous CB(1) agonists, anandamide and N-arachidonoyldopamine, which also activate transient receptor potential vanilloid type 1 (TRPV1) receptors expressed in RIN m5F cells, elevated [Ca(2+)](i) in the presence of extracellular Ca(2+) in a way sensitive to both CB(1) and TRPV1 antagonists.	cb(1)	15-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	137-142
18468662-9	2008	The CB(1) and CB(2) antagonists AM 251 and AM 630, respectively, reversed the blunting effect of AJA on evoked CGRP release, resulting in an increase of 40% and 38% over baseline, respectively.	cb(1)	4-9	calcitonin-related polypeptide alpha	Rattus norvegicus	111-115
17585904-6	2007	The endogenous CB(1) agonists, anandamide and N-arachidonoyldopamine, which also activate transient receptor potential vanilloid type 1 (TRPV1) receptors expressed in RIN m5F cells, elevated [Ca(2+)](i) in the presence of extracellular Ca(2+) in a way sensitive to both CB(1) and TRPV1 antagonists.	cb(1)	15-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	280-285
17585904-6	2007	The endogenous CB(1) agonists, anandamide and N-arachidonoyldopamine, which also activate transient receptor potential vanilloid type 1 (TRPV1) receptors expressed in RIN m5F cells, elevated [Ca(2+)](i) in the presence of extracellular Ca(2+) in a way sensitive to both CB(1) and TRPV1 antagonists.	cb(1)	270-275	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	137-142
15864349-4	2005	Activation of CB(1) in mice increases the hepatic gene expression of the lipogenic transcription factor SREBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS).	cb(1)	14-19	sterol regulatory element binding transcription factor 1	Mus musculus	104-112
17952651-5	2007	Moreover, the CB(1), CB(2), and TRVP1 receptors are expressed on microvascular endothelial cells, and their activation by 2-AG counteracts endothelin (ET-1)-induced cerebral microvascular responses (namely, Ca(2+) mobilization and cytoskeleton rearrangement).	cb(1)	14-19	endothelin 1	Mus musculus	139-149
17952651-5	2007	Moreover, the CB(1), CB(2), and TRVP1 receptors are expressed on microvascular endothelial cells, and their activation by 2-AG counteracts endothelin (ET-1)-induced cerebral microvascular responses (namely, Ca(2+) mobilization and cytoskeleton rearrangement).	cb(1)	14-19	endothelin 1	Mus musculus	151-155
16936228-7	2006	Taken together, these results suggest that concurrent ligation of CB(1) and CB(2) with either R(+)-MA or Win55 induces apoptosis via a sequence of events in MCL cells: accumulation of ceramide, phosphorylation of p38, depolarization of the mitochondrial membrane, and caspase activation.	cb(1)	66-71	mitogen-activated protein kinase 14	Homo sapiens	213-216
17434980-8	2007	Anandamide dose dependently attenuated the TNF-alpha-induced ICAM-1 and VCAM-1 expression, NF-kappaB activation in HCAECs, and the adhesion of monocytes to HCAECs in a CB(1)- and CB(2)-dependent manner.	cb(1)	168-173	tumor necrosis factor	Mus musculus	43-52
17384224-2	2007	Modeling studies have implicated Ser2.60(173) and Ser7.39(383) as possible interaction site(s) for CB(1) agonists.	cb(1)	99-104	jagged canonical Notch ligand 2	Homo sapiens	33-37
15864349-4	2005	Activation of CB(1) in mice increases the hepatic gene expression of the lipogenic transcription factor SREBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS).	cb(1)	14-19	fatty acid synthase	Mus musculus	158-177
15864349-4	2005	Activation of CB(1) in mice increases the hepatic gene expression of the lipogenic transcription factor SREBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS).	cb(1)	14-19	fatty acid synthase	Mus musculus	179-182
15864349-7	2005	In the hypothalamus, where FAS inhibitors elicit anorexia, SREBP-1c and FAS expression are similarly affected by CB(1) ligands.	cb(1)	113-118	sterol regulatory element binding transcription factor 1	Mus musculus	59-67
15864349-7	2005	In the hypothalamus, where FAS inhibitors elicit anorexia, SREBP-1c and FAS expression are similarly affected by CB(1) ligands.	cb(1)	113-118	fatty acid synthase	Mus musculus	72-75
15750287-7	2005	These results suggest that CB(1) could inhibit either the capsaicin-induced Ca(2+) influx or the potentiation of capsaicin-induced SPLI release by a long-term treatment with bradykinin through involvement of a cyclic-AMP-dependent PKA pathway.	cb(1)	27-32	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	231-234
15531093-4	2004	Superfusion of either WIN55,212-2 (1 microM) or (S)-AMPA (1 microM) significantly attenuated CGRP release in a CB(1)-dependent manner (SR141716A, 5 microM).	cb(1)	111-116	calcitonin-related polypeptide alpha	Rattus norvegicus	93-97
12834810-0	2003	Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells.	cb(1)	55-60	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	14-39
12927857-1	2003	We designed and synthesized a series of pyrrole derivatives with the aim of investigating the structure-activity relationship (SAR) for the binding of non-classical agonists to CB(1) and CB(2) cannabinoid receptors.	cb(1)	177-182	sarcosine dehydrogenase	Homo sapiens	94-131
12834810-0	2003	Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells.	cb(1)	55-60	protein tyrosine kinase 2 beta	Homo sapiens	40-43
12770562-11	2003	In conclusion, by comparing the distribution of FAAH and CB(1) in the mouse brain, we have provided a neuroanatomical framework for comparative analysis of the role of FAAH in regulation of the spatiotemporal dynamics of retrograde endocannabinoid signaling in different regions of the brain.	cb(1)	57-62	fatty acid amide hydrolase	Mus musculus	168-172
12435806-12	2002	In conclusion, CB(1)-induced ERK activation was mediated by PI3K(IB) and this effect may have important consequences in the control of cell death/survival decision.	cb(1)	15-20	mitogen-activated protein kinase 1	Homo sapiens	29-32
12388547-4	2002	The CB(1) and CB(2) agonist WIN 55,212-2 inhibited the expression of inducible NO synthase (iNOS) and NO release caused by treatment of C6 cells with HIV-1 Tat and interferon-gamma (IFN-gamma).	cb(1)	4-9	Tat	Human immunodeficiency virus 1	156-159
12388547-7	2002	Moreover, cell treatment with HIV-1 Tat + IFN-gamma induced a significant inhibition of CB(1), but not CB(2), receptor expression.	cb(1)	88-93	Tat	Human immunodeficiency virus 1	36-39
12435806-3	2002	However, the precise molecular mechanism for CB(1)-mediated ERK activation is still unknown.	cb(1)	45-50	mitogen-activated protein kinase 1	Homo sapiens	60-63
10496968-7	1999	46V</protein-id>), and a corresponding Val to Phe mutation at the position 5.46 in CB(1) (CB(1)V5.46F), were made.	cb(1)	90-95	cannabinoid receptor 1	Homo sapiens	83-88
12237305-6	2002	AEA decreased PC12 neuronal-like generation via CB(1)-mediated inhibition of sustained extracellular signal-regulated kinase (ERK) activation, which is responsible for nerve growth factor action.	cb(1)	48-53	mitogen-activated protein kinase 1	Homo sapiens	87-124
12237305-6	2002	AEA decreased PC12 neuronal-like generation via CB(1)-mediated inhibition of sustained extracellular signal-regulated kinase (ERK) activation, which is responsible for nerve growth factor action.	cb(1)	48-53	mitogen-activated protein kinase 1	Homo sapiens	126-129
12037135-3	2002	Two types of cannabinoid receptor have been discovered so far, CB(1) (2.1: CBD:1:CB1:), cloned in 1990, and CB(2) (2.1:CBD:2:CB2:), cloned in 1993.	cb(1)	63-68	cannabinoid receptor 1	Homo sapiens	81-84
11278420-8	2001	By contrast, the CB(1) receptor antagonist SR141716A inhibited also the VR1-mediated effect of anandamide and capsaicin on cytosolic Ca(2+) concentration, although at concentrations higher than those required for CB(1) antagonism.	cb(1)	17-22	vault RNA 1-1	Homo sapiens	72-75
10525080-7	1999	The CB(1)-selective antagonist SR141716A alone acted as a inverse agonist by inhibiting GIRK currents in oocytes expressing CB(1)/GIRK1/4, suggesting the CB(1) receptor is constitutively activated.	cb(1)	4-9	potassium inwardly rectifying channel subfamily J member 3 L homeolog	Xenopus laevis	88-92
10525080-7	1999	The CB(1)-selective antagonist SR141716A alone acted as a inverse agonist by inhibiting GIRK currents in oocytes expressing CB(1)/GIRK1/4, suggesting the CB(1) receptor is constitutively activated.	cb(1)	4-9	potassium inwardly rectifying channel subfamily J member 3 L homeolog	Xenopus laevis	130-137